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Many studies have investigated the effects of energy drinks on cardiovascular parameters. 
These studies were typically conducted with high volume (32 ounces) energy drinks and have 
demonstrated association with QT prolongation and blood pressure elevation after consumption. 
Currently, there is inconclusive evidence with lower volume energy drinks. This study intends 
to  evaluate the effects of the largest commercially available energy drink can (24 ounces) in the 
United States on cardiovascular parameters compared with placebo arm. A randomized, double-
blinded, placebo-controlled, crossover trial was conducted over 2 separate days with a minimum 
of 6-day wash out period. Healthy volunteers between the age of 18 and 40 randomly consumed 
either a 24 oz energy drink or 24 oz placebo control drink on different days. Subjects were 
required to fast overnight and refrain from products containing caffeine or alcohol 48 hours prior 
to each study day. ECG, peripheral and central BP, heart rate, and augmentation index were 
measured at baseline, 1, 2, 3, and 4 hours post-consumption. Primary endpoints were average 
maximum change of corrected QT (QTc) interval and peripheral systolic blood pressure (pSBP) 
from baseline. The study enrolled 20 participants with a mean age of 23±5 years. The maximum 
baseline-adjusted difference of QTc interval was significantly higher in the energy drink arm 
than the placebo arm (13.68 ± 12.71 vs 4.20 ± 8.80 ms, respectively, p = 0.007). The maximum 
baseline-adjusted difference of pSBP was significantly higher in the energy drink arm compared 
 
4 
to placebo (11.10 ± 5.24 vs 6.08 ± 7.07 mmHg, respectively; p= 0.006). Maximum baseline-
adjusted difference of central diastolic BP and systolic and diastolic BP were also statistically 
significantly higher in the energy drink arm. This study demonstrated that a single, 24-ounce can 
of an energy drink can significantly prolong the QTc interval and raise pSBP.
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Chapter 1: Introduction 
Background 
Energy drinks are beverage products that typically contain caffeine and energy-boosting 
ingredients. They are widely consumed not only in the United States (US) but also globally.  
Some energy drinks that are available in the US include Monster®, Red Bull®, 5-hour 
ENERGY®, and Rockstar® (Grasser 2016).  Energy drinks were reported to comprise 60% of 
US functional beverages’ market share, which includes market for sport drinks and nutraceutical 
beverages, and its market growth have increased by almost 250% between 2004 and 2009 
(Heckman 2010).  These products have become a regular staple for the young population groups, 
most notably adolescents, college students, and young working adults, to boost energy and curb 
fatigue.  It has been reported that over 30% of young adults age 18 to 24 years are consuming 
energy drink regularly (Heckman 2010, O’Brien 2008). 
In the past decade, the safety of energy drinks has been examined given several reports of 
adverse events and even deaths linked to consumption of energy drinks.  Most cases reported 
incidences of arrhythmia after energy drinks consumption, which had led to emergency room 
visits or deaths (Avci 2013, Israelit 2012, Goldfarb 2014, Malinauskas 2007, SAMHSA 2013, 
Seifert 2013).  Another adverse event that had been reported include the incidence of seizure, 
which can also lead to serious short-term and long-term consequences (Seifert 2013).  As of June 
2014, 34 deaths associated with energy drinks had been reported to Food and Drug 
Administration (FDA), whereas
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22 cases were linked to 5-hour ENERGY®, 11 cases to Monster® and 1 case to Rockstar® 
(CFSAN 2012). 
Currently, there is no regulation in place for energy drinks by the FDA as it is categorized as 
dietary supplements.  Most energy drinks contain caffeine as one of the major ingredients.  Other 
common ingredients that can be found in energy drinks include taurine, ginseng, l-carnitine, and 
yohimbine.  Most were claimed to boost physical performance and metabolism.  These 




Table 1: List of Energy Drink Ingredients Associated with Adverse Effects 
Ingredients Reported Adverse Effects 
Caffeine Anxiety, irritability, insomnia, tachycardia, hypertension, abnormal heart 
rhythm, palpitation, upset stomach, rigidity 
Ginseng Diarrhea, headache, vertigo, hypertension, hypersensitivity reactions, 
insomnia, irritability 
L-carnitine Upset stomach, increased seizure risk 
Taurine Lower blood pressure 




With questionable safety of energy drinks, there is huge concern regarding the consumption 
of energy drinks that are available on the market, especially there is currently no regulation in 
place.  Further investigations are warranted to fill the gaps and add knowledge to the general 
public. 
Energy Drink Effects on Cardiovascular Parameters 
Energy drinks have been previously investigated in clinical studies, mostly for their effects 
on cardiovascular parameters including heart rhythm, blood pressure (BP), and heart rate.  
Several studies have demonstrated significant effect of energy drinks in prolonging QT interval 
(Basrai 2019, Fletcher 2017, Shah 2019).  QT prolongation is an irregular heart rhythm that put 
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human subjects at risk for life-threatening arrhythmias, most commonly “Torsades de Pointes” 
(TdP) that can lead to sudden cardiac death (Nachimuthu 2012).  The incidence of TdP after 
taking QT-prolonging substances ranges between 2% and 12% (Tisdale 2016).  Prolonged 
corrected QT (QTc) interval is defined as greater than 450 milliseconds (ms) in males or 470 ms 
in females.  These values are obtained by adjusting the QT interval measurements based on 
individual’s heart rate.  QT prolongation occurs when ventricular repolarization is abnormally 
prolonged, which can trigger the myocardium to undergo early after depolarization (EAD) before 
completing the full phases of cardiac action potential.  When the EAD reaches a critical 
threshold, it can prematurely depolarize the ventricles and cause ventricular contraction.  
Overall, with desynchronization of the action potentials across the myocardium, it can create 
excitation that can lead to TdP (Nachimuthu 2012). 
The most recently published study on energy drink evaluated the cardiovascular effects of 
two commercially different energy drinks in a randomized, placebo-controlled, crossover trial 
over 24 hours.   Participants in the study received 32 ounces of drinks for each intervention.  The 
energy drinks were similar in content, except for some differences in ingredients including 
carnitine, guarana, and Panax ginseng.  The results of the study demonstrated that both energy 
drinks significantly prolong QTc interval and raise blood pressure.  These effects were mostly 
seen within 4 hours post-consumption (Shah 2019).  
Other researchers attempted to investigate specific ingredients on cardiovascular parameters.  
Fletcher and colleagues investigated effects of energy drink versus caffeinated control drink on 
QT prolongation and blood pressure elevation.  The study demonstrated a significant difference 
of the baseline-adjusted QTc interval at 2 hours and peripheral blood pressure elevation at 6 
hours (Fletcher 2017) between the energy drink and caffeinated control drink.  The study 
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suggested that caffeine might not be the likely cause of QT prolongation and there might be other 
ingredients that might have caused the QT prolongation.  Another randomized controlled trial 
comparing effects of energy drinks, Panax ginseng, and placebo on QTc prolongation showed 
significant difference of between energy drinks and placebo at 2 hours, while Panax ginseng 
alone did not contribute to QT prolongation effect (Shah 2016).  Furthermore, a randomized 
controlled trial published early this year conducted a research to investigate the effects of control 
drinks containing caffeine, glucuronolactone, or taurine alone or in combination and compare 
them energy drinks containing the same amount of the ingredients above and placebo.  Caffeine-
containing drinks were shown to raise blood pressures while when taurine is added to caffeine-
containing drinks, it was shown to shorten QTc interval and no significant difference was seen 
for systolic blood pressure.  In addition, glucuronolactone-containing drinks resulted in 
shortened QTc interval when compared to placebo (Basrai 2019). 
Most studies that have shown significant QT prolongation after energy drink consumption 
compared high-volume (32 ounces) energy drinks to placebo drinks (Fletcher 2017, Shah 2019).  
It is questionable if we can extrapolate the results obtained previously from high-volume energy 
drink studies to general public, given the largest volume of energy drinks currently available on 
the market is 24 ounces.  Wiklund et al. investigated the use of 25 ounces energy drinks in their 
study participants and show no change in heart rhythm.  The study arms include a group 
receiving energy drinks after overnight fasting and another group after 30 minutes of maximal 
exercise, a group receiving energy drinks with alcohol after 30 minutes of maximal exercise, and 
a control group receiving no drink after similar amount of exercise (Wiklund 2003).  Because of 
the complexity of the study design and interventions, there are limitations to generalize the 
results in everyday life setting.  Another study was conducted to compare 16 ounces energy 
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drinks, 24 ounces energy drinks, caffeine, and water.  The authors found no difference in 
cardiovascular measurements, including QT interval.  However, there are variabilities in the 
study interventions, such as variable volume of the fluids received by each study group or 
different caffeine content, that might affect their findings.  In addition, the study was 
underpowered, which made it less likely for small changes in the measurements to be detected 
(Brothers 2017).  Basrai and colleagues also conducted volume effects evaluation in their study 
comparing 750 milliliters (~25 ounces) and 1,000 milliliters (33 ounces) energy drinks, which 
they found to have no different on cardiovascular parameters in regard to different volumes, 
including QTc interval and blood pressure.  However, the study did not report the comparison 
results of the lower-volume drink head to head with placebo after it was determined that both 
volumes did not have different effects on their outcomes (Basrai 2019).  Given there is little 
known about the cardiovascular safety profile of 24 ounces energy drinks, further investigation 
will provide additional knowledge. 
Objective and Hypothesis 
The objective of this randomized, controlled, crossover, double-blind clinical trial is to 
compare the effect of 24-ounce energy drinks and placebo in regard to QT interval prolongation 
and BP elevation.  We hypothesize that 24-ounce energy drink will lead to greater QTc interval 
and blood pressure when compared to placebo.   
The overall purpose of the study is to gain more information regarding safety profile of 
energy drinks that are currently available in the market.  The study results may be used to help 
regulatory bodies to support or refute call to action for energy drink regulation or labeling 
standards.  
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Chapter 2: Methods 
Study Oversight 
IRB approval.  The study involved human subjects.  Research conduct was approved by 
University of the Pacific (UOP) Institutional Review Board (IRB) with protocol number 19-03.  
Informed consent.  As part of the IRB protocol, a written informed consent document was 
also generated.  The document provided information to study subjects regarding the purpose of 
the study, how the research would be conducted, eligibilities to participate in the study, 
procedures to be followed, rundown of study visit schedules, potential risks of the study, risk 
managements, compensation information, confidentiality statement, and contact information of 
primary study investigator. 
 Prior to subject enrollment, study investigators ensured subjects understand the expectations 
and risks associated with the study.  Consent was obtained from subjects by obtaining signatures 
of study subject, primary investigator, and a witness and dating the document.  A copy of the 
signed informed consent was provided to each study subject. 
Risk management.  Subjects were observed for any adverse event during the study and 
followed throughout the study period.  Safeguards were placed in order to eliminate and 
minimize the risks when subjects experienced adverse events.  In the event of minor adverse 
events, subjects were informed to notify principal investigators and were provided with 
resolution promptly when necessary.  For serious adverse events, subjects were informed to 
immediately contact 9-1-1 or go to the closest emergency department.
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All subjects were provided with the primary investigator contact information to contact to 
discuss any adverse event they might be experiencing while offsite. 
Study Population 
Recruitment.  For subject recruitment, flyers and listserv emails were distributed around the 
University of the Pacific (UOP) and Stockton community.  Locations include UOP campus, San 
Joaquin Delta College, and nearby food and beverage shops.  The contact information of the 
primary investigator was provided on the flyers and listserv emails for interested participants. 
Screening criteria.  After study subjects were consented, they were screened for eligibilities 
to participate in the study.  Healthy volunteers with no medical condition between the age of 18 
and 40 were enrolled.  Subjects were excluded if they have any risk factors for cardiovascular 
diseases, including heart rhythm other than normal sinus, history of arrhythmia, family history of 
premature sudden cardiac death before the age of 60, left ventricular hypertrophy, 
atherosclerosis, hypertension, palpitations, t-wave abnormalities, baseline QTc interval greater 
than 450 ms.  Subjects with BP greater than 140/90 millimeter mercury (mmHg), presence of 
any known medical condition, or concurrent use of any medication or herbal supplements on 
daily basis were excluded as well.  The use of oral contraceptives are permitted as long as 
subjects have been stable on it for 1 month.  Other exclusion criteria include current smoker or 
recent smoking in the month prior to enrollment, pregnancy or currently breastfeeding, non-
English speaker, refusal to sign informed consent form, and unwillingness to follow study 
protocol.  Other baseline information collected during the screening include age, height, weight, 
ethnicity, typical use of energy drink and other caffeinated beverage, average daily amount of 
sleep, and average amount of physical activity. 
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Information to determine eligibility was collected during the subject interview.  
Electrocardiogram (ECG), BP, and BG measurements were obtained to rule out exclusion 
criteria mentioned above.  A pregnancy test was also conducted using urine dip stick tests for all 
female subjects who are capable of being pregnant. 
Eligibility for study participation was determined during the screening visit and followed by 
study visits schedules.  The first study visit (Day 1) could be conducted immediately after the 
screening if subjects have met all the inclusion and exclusion criteria and study protocol 
requirements. 
Study Design 
Design.  The study design is a randomized, controlled, double-blind, crossover clinical trial.  
Subjects were assigned randomly to two study arms. On 2 separate days, each subject consumed: 
1. 24-ounces of energy drink (ingredients include 240 mg caffeine, 81 g sugar, 5.1 mg 
vitamin B2, 60 mg of vitamin B3, 6 mg of vitamin B6, 18 mcg of vitamin B12, 3000 mg 
of taurine, 600 mg of Panax ginseng, and 7,500 mg of proprietary energy blend including 
L-carnitine, glucose, caffeine, guarana, inositol, glucuronolactone, and maltodextrin)  
2. 24-oz of cherry- and lime-flavored, carbonated placebo drink (ingredients include 30 mL 
lime juice, 105 mL of cherry syrup, and 575 mL of carbonated water) 
Study products were bought from standard vendors and compounded prior to sessions.  24-
ounces energy or placebo drinks were divided into two 12-ounces tinted bottles.  Study 
investigators and subjects were blinded as to what interventions each subject received on each 
study day.  All study drinks were made and packaged by unblinded member of the study team. 
Study visit timeline.  Prior to each study visit, all subjects were required to refrain from 
caffeine, alcohol, and energy drink consumption at least 48 hours and fast overnight with no food 
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or drinks except water 10 hours prior to each study visit.  There were 2 scheduled visits with at 
least 6 days washout period between each visit for all subjects. 
During each visit, baseline measurements of ECG and BP were obtained before subjects 
consumed the study drinks.  Subjects were required to consume the drinks no faster than 15 
minutes per bottle.  The time clock for study duration started at the beginning of the drinking 
process.  Repeated measurements of cardiovascular parameters were made at an hourly interval 
over 4 hours.  In addition, assessment of any side effect experienced was also obtained hourly.  
All measurements were recorded on the subject data collection form.  Subjects were asked to 
keep activity to minimal until last measurements were collected.  Snacks were available for 
subjects when requested. 
Measurements 
Baseline characteristics.  Demographic information were collected during the screening 
visit.  History of regular caffeine or energy drink intake and sleeping pattern were also obtained 
from subject. 
Electrocardiogram.  Standard 12-lead ECG machines (Philips PageWriter Trim III and 
TC20, Philips Medical Systems, Andover, MA) were used to obtain QT interval, PR interval, 
and QRS duration. The QT interval obtained was further corrected to QTc with Bazett’s equation 





ECG measurements were conducted at baseline (0 minute), 60 minutes, 120 minutes, 180 
minutes, and 240 minutes with subjects in supine position on each study visit day.  All 
electrocardiogram measurements were taken three times at each time point and averages were 
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calculated for data analysis.  Calibration of the ECG machine was performed routinely to 1-
milliVoltage/centimeter standardization with a paper speed of 25 millimeter/second. 
SphygmoCor.  Peripheral and central blood pressures were obtained using SphygmoCor 
(AtCor Medical Pty Ltd, West Ryde, Australia).  Blood pressures were obtained at baseline (0 
minute), 60 minutes, 120 minutes, 180 minutes, and 240 minutes with subjects in relaxed sitting 
position on each study visit day.  Subjects were instructed to sit for 2 minutes after coming up 
from ECG measurements prior to SphygmoCor measurements.  All blood pressure 
measurements were taken twice at each time point and averages were calculated for data 
analysis.  In addition to blood pressures, SphygmoCor also measured heart rate and arterial 
stiffness, which was presented as augmentation index. 
Adverse events.  Subjects were observed and interviewed for any signs and symptoms of 
adverse events related to cardiovascular, gastrointestinal, and central nervous systems they might 
be experiencing during the study visits or anytime during the study period when they are offsite.  
Interview questions included presence of potential cardiovascular adverse events (tachycardia, 
elevated blood pressure, flushing sweating, or palpitations), gastrointestinal adverse events 
(nausea, vomiting, diarrhea, stomach upset, or loss of appetite), or central nervous system 
adverse events (agitation, hallucination, headache, insomnia, sleepiness, irritability, restlessness, 
dizziness, tingling sensation, or confusion).  Subjects were also asked if they were experiencing 
other potential adverse effects including signs and symptoms not mentioned above. 
Data Analysis 
Endpoints.  The primary endpoint of the study included the baseline-adjusted QTc (QTcB 
and QTcF) and peripheral systolic blood pressure (pSBP).  Other endpoints that were collected 
included baseline-adjusted QT interval, PR interval, QRS duration, hear rate, peripheral diastolic 
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blood pressure (pDBP), central systolic and diastolic blood pressure (cSBP and cDBP), and 
augmentation index corrected at heart rate of 75 beats per minute(AI75).  Any occurrence and 
description of adverse events were also recorded.  All endpoints were assessed at each 
measurement time points. 
Power calculation.  To achieve 80% power at an alpha level of 0.05 based on the primary 
endpoints of QTc and peripheral systolic BP, 18 subjects overall are needed to participate in the 
study.  Assumptions were made for the endpoints to observe significant difference in QTc and 
central systolic blood pressures when comparing energy drink and placebo with anticipated of 
baseline-adjusted QTc of 10+14 ms and systolic blood pressure of 4+4 mmHg. 
Statistical tests.  Baseline characteristics and endpoints were reported using descriptive 
statistics; percentage for discrete variables and mean with standard deviation for continuous 
variables.  Shapiro-Wilk test was used to determine normal distribution of the data  given small 
sample size.  Wilcoxon test was used to detect statistical difference for electrocardiogram and 
SphygmoCor endpoints while Chi-square test was used for adverse events.  Both per protocol 
and intention to treat analyses were conducted for the baseline-adjusted maximum difference of 
endpoints between the energy drink and placebo arms.  Mann-Whitney U test was used to 
determine any effect of randomization and duration of drinking on outcomes.  Data collection 
and analysis were performed with Microsoft Excel (Version 16.10, Microsoft, Redmond, WA) 
and SPSS (Version 25, IBM Corporation, Armonk, New York).  
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Chapter 3: Results 
Enrollment and Randomization 
Twenty two subjects were screened for the study and 20 subjects met inclusion and exclusion 
criteria to be enrolled. Two subjects were excluded, one subject has a diagnosis of irritable bowel 
diseases and another subject’s average QTc obtained during screening was greater than 450 ms. 
All enrolled subjects completed the study with no withdrawal. 
Nine subjects (45%) received energy drinks on their first visit and then placebo drink in the 
second visit and 11 subjects (55%) vice versa. Most subjects on both visit days completed the 
drinks within 30 minutes. Five subjects (25%) completed the energy drinks and 3 subjects (15%) 
completed the placebo drinks after 30 minutes. All subjects completed the drinks within 60 
minutes before the first measurement timepoint. 
Baseline Characteristics 
As presented in Table 2, subjects enrolled were 23 years old on average with even split in 
gender. Majority of the subjects (55%) were Asians, followed by Caucasian and  few are African 
American and Hispanic. Most of the subjects (70%) rarely consumed energy drinks but most 
(75%) consumed other caffeinated beverage either occasionally or frequently.  In terms of 
baseline cardiovascular parameters (refer to Table 3), all heart rhythm and blood pressure 
measurements were similar between the energy drinks and placebo arms (p>0.05).  
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Table 2: Baseline Characteristics 
Characteristics Total (n = 20) 
Age (in year) 22.55 ± 5.37 
Height (in inch) 66.90 ± 3.29 
Weight (in pound) 160.14 ± 32.55 











Energy drink consumption 
Rarely (<1 drink per month) 
Occasionally (1-3 drinks per month) 
Frequently (1-6 drinks per week) 






Non-energy drink caffeinated drink consumption 
Rarely (<1 drink per month) 
Occasionally (1-3 drinks per month) 
Frequently (1-6 drinks per week) 






Physical activity (in day per week) 3.78 ± 1.48 
Amount of sleep (in hour per day) 6.26 ± 0.78 




Table 3: Baseline Cardiovascular Parameters 
 ED (n = 20) PL (n = 20 for ECG and 
19 for SphygmoCor) 
P value 
QTcB (ms) 423.27 ± 16.07 420.33 ± 18.94 0.247 
QTcF (ms) 419.66 ± 14.84 419.31 ± 16.97 0.911 
QT (ms) 413.63 ± 33.93 418.48 ± 33.29 0.952 
PR (ms) 156.10 ± 20.11 154.00 ± 21.57 0.112 
QRS (ms) 92.67 ± 8.88 93.22 ± 8.72 0.866 
pSBP (mmHg) 117.93 ± 10.30 116.90 ± 11.00 0.420 
pDBP (mmHg) 72.45 ± 6.18 71.74 ± 7.16 0.445 
cSBP (mmHg) 104.40 ± 9.27 103.24 ± 10.29 0.227 
cDBP (mmHg) 73.17 ± 6.03 72.64 ± 7.14 0.601 
HR (bpm) 65.47 ± 11.68 65.23 ± 12.90 0.494 
AI75 5.07 ± 16.33 2.50 ± 17.82 0.227 
All data are reported in mean ± SD. Abbreviation: AI75, augmentation index corrected at heart 
rate of 75 beats per minute; bpm, beats per minute; cDBP, central diastolic blood pressure; cSBP, 
central systolic blood pressure; ED, energy drink; HR, heart rate; mm Hg, millimeter mercury; 
ms, millisecond; pDBP, peripheral diastolic blood pressure; PL, placebo; PR, PR interval; pSBP, 
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peripheral systolic blood pressure; QRS, QRS duration; QT, QT interval; QTcB, corrected QT 





Normality.  Normality test was conducted that shows ECG data from 20 subjects were not 
all normally distributed. It was then determined that nonparametric tests were needed to conduct 
data analysis. 
Electrocardiogram.  Baseline-adjusted ECG measurements at each timepoint are presented 
in Table 4 and Figure 1. Baseline-adjusted QTcB and QTcF were found to be significantly 
greater in energy drink arm compared to placebo arm at hour 1, 2, and 3 and hour 4 for QTcF as 
well. In addition, baseline-adjusted QT interval was found to be significantly greater in energy 
drink arm at hour 1.  Baseline-adjusted PR interval and QRS duration were similar between 
group at any timepoint. 
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Table 4: Baseline-Adjusted Electrocardiogram Measurements at Each Timepoint 
  1 Hour 2 Hour 3 Hour 4 Hour 
QTcB ED (n = 20) 5.85 ± 11.66 1.77 ± 12.19 5.62 ± 15.10 3.38 ± 3.00 
PL (n = 20) -1.35 ± 8.24 -6.27 ± 9.66 -4.00 ± 11.46 -1.08 ± 2.59 
Mean 
Difference 
7.20 ± 9.27 8.03 ± 13.45 9.62 ± 12.51 4.47 ± 16.91 
P value 0.003* 0.014* 0.004* 0.502 
QTcF ED (n = 20) 2.69 ± 6.42 -1.27 ± 8.04 6.63 ± 11.76 6.61 ± 10.29 
PL (n = 20) -3.47 ± 5.68 -7.37 ± 6.97 -1.80 ± 10.00 0.71 ± 10.07 
Mean 
Difference 
6.16 ± 6.85 6.10 ± 8.82 8.43 ± 10.41 5.90 ± 10.07 
P value 0.002* 0.005* 0.001* 0.019* 
QT ED (n = 20) -3.41 ± 
14.33 
-7.43 ± 17.54 8.43 ± 18.18 12.93 ± 25.68 
PL (n = 20) -7.58 ± 
15.55 
-9.53 ± 14.67 2.72 ± 20.94 4.27 ± 20.89 
Mean 
Difference 
4.18 ± 10.08 2.10 ± 15.10 5.72 ± 22.10 8.67 ± 25.07 
P value 0.019* 0.422 0.305 0.126 
PR ED (n = 20) 0.20 ± 6.26 -3.05 ± 5.71 -3.43 ± 6.53 -3.42 ± 7.82 
PL (n = 20) 2.70 ± 6.50 -2.13 ± 7.90 -3.75 ± 4.91 -5.75 ± 6.26 
Mean 
Difference 
-2.50 ± 7.00 -0.92 ± 9.53 0.32 ± 8.33 2.33 ± 9.43 
P value 0.089 0.695 1.000 0.286 
QRS ED (n = 20) 2.78 ± 2.85 0.10 ± 2.34 0.73 ± 3.14 1.38 ± 3.54 
PL (n = 20) 3.93 ± 3.18 1.38 ± 2.84 0.42 ± 4.00 1.42 ± 4.05 
Mean 
Difference 
-1.15 ± 3.00 -1.28 ± 2.73 0.32 ± 4.40 -0.03 ± 3.43 
P value 0.140 0.050 0.546 0.840 
All data are reported in mean ± SD in millisecond unit. Abbreviation: ED, energy drink; ms, 
millisecond; PL, placebo; PR, PR interval; QRS, QRS duration; QT, QT interval; QTcB, 














































Energy Drink Placebo(d) 
Figure 1: Baseline-adjusted electrocardiogram parameters at timepoints of 1, 2, 3, and 4 hours of (a) 
QTcB (corrected QT interval with Bazett’s equation), (b) QTcF (corrected QT interval with 
Fridericia’s equation), (c) QT (QT interval), (d) PR (PR interval), and (e) QRS (QRS duration). 
Abbreviation: ms, millisecond. 



































The maximum change from baseline in QTcB was significantly greater in energy drink arm 
compare to placebo with mean difference of 9.48 ± 13.84 ms (p = 0.007).  Similarly, QTcF was 
found to be greater in energy drink arm (7.13 ± 10.55 ms, p = 0.006). QT interval, PR interval, 
and QRS duration were similar between arms (Table 5). 
Per protocol analysis (Table 6) for ECG measurements was conducted due to incomplete 
data collection for one subject in the energy arm, specifically for the first measurement timepoint 
1 hour post-consumption.  Analysis demonstrated similar results as intention to treat analysis in 
terms of maximum change of QTcB and QTcF from baseline being significantly greater in 
energy drink arm and no difference was noted for PR interval, QT interval, and QRS duration.  
In addition, baseline-adjusted measurements at hour 1 show similar results when compared to 
intention-to-treat analysis where significant difference was observed for QTcB, QTcF, and QT 
interval, but no difference found for PR interval and QRS duration. 
Two female and 1 male subjects had prolonged QTc within 4 hours after consuming energy 
drink at 493.67, 477.33, and 410.67 ms, respectively, with changes from baseline of over 30 ms.  
No subject was found with prolonged QTc interval in placebo arm, except for one female subject 
with prolonged QTc interval at baseline (474.33 ms) that is maintained throughout the study 




Table 5: Intention-To-Treat Average Maximum Change in Electrocardiogram Measurements 
 ED (n = 20) PL (n = 20) Mean Difference P value 
QTcB 13.68 ± 12.71 4.20 ± 8.80 9.48 ± 13.84 0.007* 
QTcF 10.59 ± 9.41 3.42 ± 8.41 7.17 ± 10.51 0.006* 
QT 16.50 ± 21.93 7.25 ± 19.21 9.25 ± 23.87 0.135 
PR 2.07 ± 6.36 4.57 ± 4.23 -2.50 ± 5.74 0.086 
QRS -6.47 ± 33.00 4.35 ± 2.87 -10.82 ± 34.23 0.513 
All data are reported in mean ± SD and in millisecond unit. Abbreviation: ED, energy drink; ms, 
millisecond; PL, placebo; PR, PR interval; QRS, QRS duration; QT, QT interval; QTcB, 
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Table 6: Per-Protocol Analysis of Change in Electrocardiogram Measurements 
  1 Hour 
(n = 19 for ED and n = 20 for PL) 
Maximum 
(n = 20) 
QTcB ED 6.28 ± 11.81 13.68 ± 12.70 
PL -1.04 ± 8.34 4.20 ± 8.80 
Mean 
Difference 
7.32 ± 9.51 9.48 ± 13.84 
P value 0.005* 0.007* 
QTcF ED 2.51 ± 6.54 10.59 ± 9.41 
PL -3.54 ± 5.82 3.42 ± 8.41 
Mean 
Difference 
6.05 ± 7.02 7.17 ± 10.51 
P value 0.004* 0.006* 
QT ED -4.63 ± 13.61 16.50 ± 21.93 
PL -8.32 ± 15.62 7.25 ± 19.21 
Mean 
Difference 
3.68 ± 10.11 9.25 ± 23.87 
P value 0.030* 0.135 
PR ED -0.25± 6.10 2.07 ± 6.36 
PL 2.33 ± 6.47 4.57 ± 4.23 
Mean 
Difference 
-2.58 ± 7.18 -2.50 ± 5.74 
P value 0.112 0.086 
QRS ED 2.40 ± 2.35 3.57 ± 3.15 
PL 3.70 ± 3.09 4.35 ± 2.87 
Mean 
Difference 
-1.30 ± 3.01 -1.28 ± 2.73 
P value 0.083 0.108 
All data are reported in mean ± SD and in millisecond unit. Abbreviation: ED, energy drink; ms, 
millisecond; PL, placebo; PR, PR interval; QRS, QRS duration; QT, QT interval; QTcB, 






SphygmoCor.   Baseline-adjusted SphygmoCor measurements at each timepoint were 
presented in Table 7 and Figure 2. Baseline-adjusted peripheral blood pressures and cDBP were 
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found to be significantly greater in energy drink arm compared to placebo arm at hour 1 and 2. 




Table 7: Baseline-Adjusted SpygmoCor Measurements at Each Timepoint 
  1 Hour 2 Hour 3 Hour 4 Hour 
pSBP (mmHg) ED (n = 20) 7.05 ± 6.36 5.80 ± 5.20 5.78 ± 6.34 6.63 ± 5.70 
PL (n = 20) 3.28 ± 7.34 0.95 ± 6.81 1.88 ± 7.15 3.35 ± 7.40 
Mean 
Difference 
3.78 ± 6.74 4.85 ± 8.74 3.90 ± 10.08 3.28 ± 8.81 
P value 0.024* 0.027* 0.112 0.142 
pDBP (mmHg) ED (n = 20) 3.33 ± 4.74 4.13 ± 4.68 2.40 ± 5.34 3.78 ± 5.00 
PL (n = 20) 1.38 ± 4.10 0.13 ± 3.94 0.55 ± 4.14 1.70 ± 5.99 
Mean 
Difference 
1.95 ± 4.33 4.00 ± 5.47 1.85 ± 6.10 2.08 ± 5.87 
P value 0.052 0.003* 0.286 0.163 
cSBP (mmHg) ED (n = 20) 4.20 ± 4.44 3.75 ± 5.26 3.16 ± 5.46 4.37 ± 5.29 
PL (n = 20) 1.07 ± 5.81 -6.91 ± 6.00 0.29 ± 5.93 1.72 ± 7.19 
Mean 
Difference 
3.13 ± 6.17 4.44 ± 8.14 2.87 ± 9.09 2.65 ± 8.49 
P value 0.057 0.052 0.167 0.296 
cDBP (mmHg) ED (n = 20) 3.67 ± 4.63 4.63 ± 4.45 2.54 ± 5.25 4.03 ± 4.88 
PL (n = 20) 1.59 ± 4.17 0.40 ± 3.84 0.63 ± 4.56 1.83 ± 6.01 
Mean 
Difference 
2.08 ± 4.17 4.24 ± 5.06 1.91 ± 6.46 2.20 ± 5.72 
P value 0.037* 0.001* 0.247 0.135 
HR (bpm) ED (n = 20) 4.47 ± 5.84 3.65 ± 6.77 -0.51 ± 8.45 -1.61 ± 9.20 
PL (n = 20) 3.40 ± 6.26 1.80 ± 5.97 -1.57 ± 6.11 -2.37 ± 6.03 
Mean 
Difference 
1.07 ± 6.97 1.85 ± 9.37 1.06 ± 9.94 0.76 ± 10.92 
P value 0.351 0.313 0.575 0.765 
AI75 ED (n = 20) -8.37 ± 5.76 -8.25 ± 8.41 -10.20 ± 6.71 -10.09 ± 9.38 
PL (n = 20) -8.78 ± 7.58 -8.35 ± 10.39 -8.68 ± 10.64 -8.62 ± 14.85 
Mean 
Difference 
0.41 ± 9.91 0.10 ± 12.57 -1.52 ± 13.45 -1.47 ± 16.86 
P value 0.737 0.970 0.627 0.970 
All data are reported in mean ± SD. Abbreviation: AI75, augmentation index corrected at heart 
rate of 75 beats per minute; bpm, beats per minute; cDBP, central diastolic blood pressure; cSBP, 
central systolic blood pressure; ED, energy drink; HR, heart rate; mm Hg, millimeter mercury; 














































































Energy Drink Placebo(b) 
Figure 2: Baseline-adjusted SphygmoCor parameters at timepoints of 1, 2, 3, and 4 hours of (a) 
pSBP (peripheral systolic blood pressure), (b) pDBP (peripheral diastolic blood pressure), (c) cSBP 
(central systolic blood pressure), (d) cDBP (central diastolic blood pressure), (e) HR (heart rate), and 
(f) AI75 (augmentation index corrected at heart rate of 75 beats per minute). 
Abbreviation: bpm, beats per minute; mm Hg, millimeter mercury. 























The maximum change from baseline in pSBP was significantly greater in energy drink arm 
compare to placebo with mean difference of 5.03 ± 9.38 mmHg (p = 0.006).  Similarly, pDBP, 
cSBP, and cDBP were found to be greater in energy drink arm. HR and AI75 were similar 
between arms (Table 8). 
Per protocol analysis (Table 9) for SphygmoCor measurement was also conducted due to 
incomplete data collection for one subject.  Analysis demonstrated similar results as intention to 
treat analysis in terms of maximum change of all blood pressures from baseline being 
significantly greater in energy drink arm and no difference was noted for HR and AI75. 
Three subjects had peripheral blood pressure of greater than 140/90 mmHg within 4 hours 
after consuming energy drinks at 145/92, 154/92, and 145/93 mmHg, while 9 subjects with 
greater than 130/80 mmHg.  Changes from baseline of pSBP ranged between 8 and 23 mmHg 
while changes from baseline of pDBP ranged between 13 and 15 mmHg for those reaching more 
than 140/90 mmHg.  None of the subjects in placebo arms had peripheral blood pressure greater 
than 140/90 mmHg, while 3 subjects had pSBP greater than 130 mmHg and 3 subjects had 




Table 8: Intention-To-Treat Average Maximum Change in SphygmoCor Measurements 
 ED (n = 20) PL (n = 20) Mean Difference P value 
pSBP (mmHg) 11.10 ± 5.24 6.08 ± 7.07 5.03 ± 9.38 0.006* 
pDBP (mmHg) 6.88 ± 4.61 3.93 ± 4.55 2.95 ± 6.02 0.033* 
cSBP (mmHg) 7.96 ± 5.08 3.79 ± 6.36 4.17 ± 9.08 0.037* 
cDBP (mmHg) 7.16 ± 4.48 4.24 ± 4.50 2.92 ± 5.86 0.021* 
HR (bpm) 7.02 ± 5.18 5.33 ± 6.65 1.70 ± 7.91 0.279 
AI75 -4.06 ± 6.76 -3.36 ± 11.78 -0.70 ± 12.76 0.823 
All data are reported in mean ± SD. Abbreviation: AI75, augmentation index corrected at heart 
rate of 75 beats per minute; bpm, beats per minute; cDBP, central diastolic blood pressure; cSBP, 
central systolic blood pressure; ED, energy drink; HR, heart rate; mmHg, millimeter mercury; 








Table 9: Per-Protocol Average Maximum Change in SphycomoCor Measurements 
 ED (n = 19) PL (n = 19) Mean Difference P value 
pSBP (mmHg) 11.05 ± 5.38 5.76 ± 7.12 5.29 ± 9.56 0.006* 
pDBP (mmHg) 6.45 ± 4.31 3.34 ± 3.83 3.11 ± 6.14 0.033* 
cSBP (mmHg) 7.93 ± 5.22 3.32 ± 6.17 4.61 ± 9.10 0.020* 
cDBP (mmHg) 6.75 ± 4.20 3.66 ± 3.79 3.09 ± 5.97 0.020* 
HR (bpm) 6.84 ± 5.25 5.17 ± 6.79 1.67 ± 8.12 0.334 
AI75 -4.14 ± 6.93 -3.76 ± 11.96 -0.38 ± 13.03 0.687 
All data are reported in mean ± SD. Abbreviation: AI75, augmentation index corrected at heart 
rate of 75 beats per minute; bpm, beats per minute; cDBP, central diastolic blood pressure; cSBP, 
central systolic blood pressure; ED, energy drink; HR, heart rate; mmHg, millimeter mercury; 






Effects of randomization and drinking duration.  No difference of average maximum 
change in ECG and SphygmoCor measurements was found between the group who received 
energy drinks and those received placebo drink first (p>0.05 for all endpoints when compared 
between groups).  Similarly, no difference was observed on all average maximum change in 
ECG and SphygmoCor measurements between group that complete energy drink within 30 
minutes versus those that complete the drinks longer than 30 minutes (p>0.05 for all endpoints 
when compared between groups). 
Adverse Events 
Overall, significant proportions of subjects receiving energy drinks reported adverse events 
compared to those receiving placebo drinks (90% vs. 30%, p<0.001).  More subjects receiving 
energy drinks experienced cardiovascular and central nervous system adverse events as shown in 
Table 10.  Most notable cardiovascular adverse events being reported were faster heartbeat, 
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while report for central nervous system adverse events include lightheadedness and restlessness 
after energy drink consumption.  More subjects receiving energy drinks were also complaining 
on experiencing nausea.  All adverse events were reported during the study visits, except for one 
subject who reported vomiting at the night of study visit after receiving placebo drink.  None of 
the adverse events resulted in discontinuation of any study participant. 
A number of subjects reported feeling hungry due to overnight fasting and snacks were 
provided upon requests.  Five subjects in each energy drink and placebo arm were provided with 
snacks that include Nature Valley granola bar and/or Orchard Valley Harvest trail mix.  One 
subject brought own snacks including banana and madeline that were verified and approved to be 
consumed during study visit by research investigator.  One subject was accidentally provided 
with Quaker granola bar that contained chocolate chip on first study visit day.  Given chocolate 
chip contains caffeine and may interfere with study results, subject was provided with similar 






Table 10: Adverse Event Reports 
Adverse Events ED (n = 20) PL (n = 20) P value 
Cardiovascular  11 (55%) 1 (5%) 0.001* 
Faster heartbeat 9 (45%) 1 (5%) 0.003* 
Sweating 1 (5%) 0 (0%) 0.311 
Palpitation 1 (5%) 0 (0%) 0.311 
Central Nervous System 13 (65%) 5 (25%) 0.011* 
Agitation 2 (10%) 0 (0%) 0.147 
Headache 1 (5%) 1 (5%) 1.000 
Lightheadedness 4 (20%) 0 (0%) 0.035* 
Restlessness 9 (45%) 1 (5%) 0.003* 
Tremor 2 (10%) 0 (0%) 0.147 
Lethargy 0 (0%) 3 (15%) 0.072 
Gastrointestinal 7 (35%) 3 (15%) 0.144 
Bloating 1 (5%) 1 (5%) 1.000 
Nausea 4 (20%) 0 (0%) 0.035* 
Vomiting 0 (0%) 1 (5%) 0.311 
Loss of appetite 1 (5%) 0 (0%) 0.311 
Upset Stomach 0 (0%) 1 (5%) 0.311 
Others 5 (25%) 2 (10%) 0.212 
More frequent urination 3 (15%) 2 (10%) 0.633 
Heavier breathing 2 (10%) 0 (0%) 0.147 
All data are reported in n (%). Abbreviation: ED, energy drink; PL, placebo. 
*p<0.05  
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Chapter 4: Discussion 
Study Impact 
  The present study investigated the cardiovascular effects of low volume energy drinks on 
healthy individuals in a controlled setting.  By far, most studies that show association of energy 
drinks with concerning cardiovascular effects investigated higher volume energy drinks, 
typically 32 ounces.  Our study show that even lower-volume, 24-ounces energy drink may be 
capable of prolonging QTc interval and raising blood pressure significantly. 
 The results of this study are comparable to those from trials investigating high volume 
energy drinks.  In a randomized controlled trial that enrolled 34 subjects and measured 
cardiovascular parameters for 4 hours post-consumption, 2 different energy drinks were shown 
to prolonged QTc interval when compared to placebo by 6 to 7.6 ms (p = 0.005). In the same 
study, blood pressures, including pSBP, pDBP, cSBP, and cDBP, were also significantly greater 
after energy drink consumption when compared to placebo (p<0.001). pSBP was found to be 
greater in energy drink arm by 4.6 to 6.1 mmHg.  It was noted that when compared to placebo, 
changes from baseline in QTc interval were specifically greater at 3, 3.5, and 4 hours while 
changes in pSBP were significant at all measurement timepoints post-consumption (Shah 2019).  
Another trial comparing energy drink, Panax ginseng, and placebo also demonstrated significant 
prolongation of QTc interval by 6.56 ms and elevation of pSBP by 4.67 mmHg (p<0.033), 
specifically 2 hours after consuming energy drink when compared to placebo (Shah 2016).  
Basrai and colleagues found that 1,000 mL (~33 ounces) energy drink significantly raised 
peripheral blood pressures and heart rate (p<0.05) 1 hours post-consumption when compared to 
control drink, while no difference was observed for QTc interval. However, the study only 
measured endpoints 1, 3, 7, and 11 hours after consumption, thus effects of drinks between hour 
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1 and 3 were not captured in the study (Basrai 2019).  Our study demonstrated similar results 
where maximum changes from baseline of QTc and blood pressures were significantly greater in 
energy drink arm than placebo arm, but no difference in heart rate was observed.  In our study 
population, prolonging QTc interval was specifically observed in the first 3 hours post-
consumption, while elevation of peripheral blood pressures in the first 2 hours post- 
consumption. 
In contrast to few studies investigating lower volume energy drinks, our study demonstrated 
significant effect of energy drink on cardiovascular parameters.  A study comparing 16 and 24 
ounces energy drinks, caffeinated drink, and water as placebo demonstrated that energy drinks at 
either volume did not significantly affect blood pressure or QTc interval when compared to 
either caffeinated drink or water (Brothers 2017). Other study with even lower size of energy 
drinks of 500 mL (~16 ounces) show no significant effect on cardiovascular parameters.  A 
randomized controlled trial, enrolling 24 subjects with familial long QT syndrome, found 
significantly higher peripheral blood pressures in energy drink arm compared to control drink 
with an increase of 6 mmHg (p = 0.046) but no significant change in primary endpoint of QTc 
interval (Gray 2017).  Steinke and colleagues found a significant changes of blood pressure, 
heart rate, and QTc interval from baseline in a study evaluating the effect of 500 mL (~16 
ounces) energy drinks over 4 hours post-consumption. The study, however, did not include a 
placebo arm.  Other than volume difference, the study also noted different amount of taurine and 
caffeine in their energy drink versus ours (Steinke 2009).  Given lack of evidence regarding the 
effect of each energy drink ingredient on cardiovascular parameters, it is possible that different 
amount of the ingredients might affect study outcomes. 
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This study might be the only randomized controlled study that specifically investigate 24 
ounces energy drink and demonstrated negative impact of energy drink on both QTc interval and 
blood pressures.  The results add confirmation to safety concerns associated with energy drinks 
and thus, warrants the need to increase awareness on risk associated with regular consumption.  
Even though prolongation QTc interval is not a fatal condition, it is a big risk factor for 
development for life-threatening arrhythmia, especially for high-risk individuals.  Many QT-
prolonging medications that induce QTc prolongation of at least 6 ms carry black box warnings 
or were removed from the market by FDA (Avelox1999, Li 2017).  Given these facts, it is 
concerning to observe that 24-ounces energy drink consumptions in our study were able to 
induce over an average of 7 ms QTc prolongation when they are not regulated and available to 
be freely purchased by general public. 
Furthermore, energy drinks impact on blood pressure cannot be ignored either.  Although the 
changes from baseline were small, but small changes can make a big difference considering 
recent update in hypertension guideline with stricter blood pressure cutoff for diagnosis of 
hypertension (Whelton 2018).  In our study, almost half of our study participants would fall 
above the blood pressure cutoff for hypertension diagnosis of greater than 130/80 after 
consuming energy drinks.  Even though it was noted that increase in blood pressures were only 
maintained for approximately 2 hours after energy drink consumption, the effect of regular or 
chronic consumption of energy drinks to blood pressures is still unknown. 
Study Limitations 
Though our study evaluated the largest can of energy drinks available in the market, 
consuming 24 ounces of energy drinks at once may not be the typical consumption pattern in the 
general population.  Most accessible marketplace, such as convenience or grocery stores, usually 
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carry even lower volume of energy drinks in 8 or 16 ounces.   In addition, our study only 
evaluated one brand of energy drink while there are many that are commercially available that 
might contain different ingredients with different amount.  There were not many studies 
available that investigate each ingredient in energy drinks and there is controversy regarding the 
effects of some ingredients on cardiovascular parameters (Basrai 2019, Fletcher 2017, Shah 
2016).  Therefore, there were still safety concerns regarding the ingredients used in energy 
drinks. 
Our study population might not be the best representative of US population given majority of 
participants were Asians.  Additionally, only as small number of our study participants reported 
consuming energy drinks regularly.  It is questionable if regular energy drink consumers would 
experience similar effects from energy drinks and it is unknown if chronic consumption of 
energy drinks would have affected acute changes of cardiovascular parameters.  Given our study 
had a set of inclusion and exclusion criteria,  all of the participants were considered healthy with 
no concurrent medications taken.  Our study results may not be applicable for those who might 
have comorbidities or taking medical products that might have possible interactions with energy 
drink or its ingredients. 
A limitation of the study protocol is that there is no maximum time allowed for subjects to 
complete their drinks.  Therefore, some participants have varying amount of time they took to 
complete the drinks.  This might affect energy drink distribution and the timing of its 
cardiovascular effects.  However, subgroup analysis was performed that shows the duration for 
completing energy drinks did not affect cardiovascular parameters.  It was also observed that 
some participants, who were familiar with energy drink taste, were able to notice the drinks they 
received and possible self-unblinded during the study period. 
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Conclusion 
This study suggested that lower volume (24 ounce) energy drinks may have acute effects on 
prolonging QTc interval and raising blood pressures after consumption.  Given the results of our 
study, regular energy drink consumers and high-risk individuals to serious cardiovascular events 
should be aware of the risk of consumption.  Further investigations are warranted, especially to 
evaluate the ingredients in energy drinks and chronic consumption of energy drinks.  
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